Discovery of Galloyl–Flavonoid Conjugates as SARS-CoV-2 3CLpro Inhibitors: Understanding Binding Interactions Through Computational Approaches
Open Access
- 7 October 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9742
Abstract
The emergence of SARS-CoV-2 in 2019 posed significant global public health challenges. One of the most promising targets for novel antiviral drug development is the SARS-CoV-2 main protease (3CLpro). In this study, fragment molecular orbital (FMO) calculations were conducted to provide guidance for the structural modification of natural flavonoids, identifying the pyrogallol moiety as a key candidate. Natural flavonoids were chemically modified to generate 33 semi-synthetic derivatives through the introduction of various functional groups. Our findings revealed that the incorporation of a galloyl moiety significantly enhances anti-proteolytic activity against SARS-CoV-2 3CLpro, achieving up to a 23-fold increase compared to the activity of the parent compounds. Notably, 7-O-galloyl-DMC (40) exhibited the highest anti-proteolytic activity in an enzymatic assay. Additionally, molecular dynamics simulations provided atomic-level insights into the interactions between the galloyl moiety and 3CLpro. All galloylated flavonoid derivatives positioned their galloyl groups within the S1′ sub-pocket, facilitating hydrogen bonding and π-interactions, particularly with Thr26 and Leu27. These findings underscore the potential of the galloyl moiety as a crucial structural element for enhancing the binding affinity of flavonoids with inhibitory activity against SARS-CoV-2 3CLpro.Keywords
Funding Information
- National Research Council of Thailand (N35A650136)
- Fundamental Fund 2025, Chiang Mai University (N35A650136)
This publication has 47 references indexed in Scilit:
- Plant flavonoid inhibition of SARS-CoV-2 main protease and viral replicationiScience, 2023
- Impacts of the COVID-19 pandemic on the social sphere and lessons for crisis management: a literature reviewNatural Hazards, 2023
- Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?Biomedicine & Pharmacotherapy, 2023
- Paxlovid: antiviral combination for the treatment of COVID ‐19Prescriber, 2022
- Potential SARS-CoV-2 main protease inhibitorsDrug Discovery Today, 2021
- The SARS-CoV-2 outbreak: What we knowInternational Journal of Infectious Diseases, 2020
- Improvements to the APBS biomolecular solvation software suiteProtein Science, 2017
- Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathwaysMolecular Biology Reports, 2014
- Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected DiseasesChemMedChem, 2008
- Exploring protein native states and large‐scale conformational changes with a modified generalized born modelProteins: Structure, Function, and Bioinformatics, 2004